Blood Glucose Monitoring Market: Charting Growth Amid Rising Diabetes Prevalence
The global Blood Glucose Monitoring Market is entering a phase of sustained expansion, driven by the growing worldwide burden of diabetes and rapid advances in monitoring technology. As health systems and patients alike prioritize continuous, accurate, and less invasive ways to track glucose levels, device makers are racing to bring smarter, more connected solutions to market. From wearable sensors to app-integrated monitors, the industry is being reshaped by a wave of innovation aimed at making diabetes management simpler and more proactive rather than reactive.
Market Size and Growth Trajectory
The blood glucose monitoring system market was valued at USD 18.03 billion in 2025, according to Fortune Business Insight, and is projected to grow from USD 18.93 billion in 2026 to USD 32.59 billion by 2034. This translates to a compound annual growth rate (CAGR) of 7.00% over the forecast period, according to Fortune Business Insight. Such steady growth reflects the widening base of diabetic patients globally, alongside improved healthcare access and rising expenditure on chronic disease management.
North America currently leads the global landscape, commanding a market share of 44.20% in 2025, according to Fortune Business Insight. The region generated USD 7.96 billion in 2025 and is expected to reach USD 8.42 billion in 2026, according to Fortune Business Insight. Europe followed as the second-largest contributor, posting USD 5.81 billion in 2025 and representing 32.20% of global revenue, according to Fortune Business Insight. Asia Pacific, while smaller in absolute terms at USD 2.92 billion and a 16.20% share in 2025, according to Fortune Business Insight, is expected to be one of the fastest-growing regions going forward.
What's Fueling the Growth?
The single biggest driver behind this market's expansion is the sheer scale of the global diabetes epidemic. Approximately 589.0 million adults aged 20–79 were living with diabetes worldwide in 2024, according to Fortune Business Insight. This enormous and growing patient pool needs consistent monitoring, whether through traditional finger-prick testing or newer continuous glucose monitoring (CGM) systems, to manage their condition effectively and avoid complications.
Technological innovation is another major catalyst. Companies such as F. Hoffmann-La Roche Ltd., Abbott, and Dexcom, Inc. are investing heavily in R&D to develop next-generation monitoring systems, according to Fortune Business Insight. These efforts are increasingly focused on integrating artificial intelligence, improving sensor accuracy, and extending wear time, all of which make monitoring less burdensome for patients while providing richer data for clinical decision-making.
Continuous glucose monitoring systems, in particular, are pulling ahead of traditional self-monitoring blood glucose (SMBG) devices. The CGM segment is projected to hold a 63.76% share of the market in 2026, according to Fortune Business Insight, thanks to its real-time tracking, minimally invasive design, and improved precision compared with older testing methods. On the patient side, the type 2 diabetes segment is expected to account for 76.28% of the market in 2026, according to Fortune Business Insight, underscoring how lifestyle-related diabetes continues to dominate the overall disease burden.
Challenges Facing the Industry
Despite this optimistic outlook, the market isn't without hurdles. Cost remains a significant barrier, especially in developing economies. The average yearly cost of a continuous glucose monitor can range from USD 2,000 to USD 7,000, according to Fortune Business Insight, a price point that puts advanced monitoring out of reach for many patients in lower-income regions. This disparity is stark in places like Kenya and South Africa, where only 16.0% of individuals with type 1 diabetes in South Africa use CGMs for disease management, according to Fortune Business Insight.
Another persistent challenge is the large undiagnosed diabetic population. Globally, roughly 240 million individuals are living with undiagnosed diabetes, according to Fortune Business Insight, meaning nearly half of all people with the condition remain unaware of their illness. This gap limits the addressable market for monitoring devices and points to a need for greater screening and awareness campaigns, particularly in low- and middle-income countries where healthcare infrastructure and diagnostic access remain limited.
Regulatory fragmentation also poses difficulties. The absence of standardized global regulations for glucose monitoring devices creates inconsistencies in product approvals across regions, occasionally allowing devices to reach the market without robust clinical validation. This is compounded by ongoing accuracy concerns surrounding non-invasive monitoring technologies, which continue to face scrutiny from regulators such as the U.S. Food and Drug Administration.
The Road Ahead: Non-Invasive Innovation
One of the most promising frontiers in this space is the development of non-invasive CGM technology. Current SMBG and invasive CGM systems, while effective, often cause pain and inconvenience that reduce patient adherence. This has opened the door for companies to explore alternative methods of glucose detection through tears, sweat, and saliva using techniques such as Raman spectroscopy.
Progress is already visible. In May 2025, Afon Technology launched Glucowear, a non-invasive glucose sensor capable of continuously tracking blood sugar levels in real time, according to Fortune Business Insight. Meanwhile, adoption of CGM devices for general wellness purposes, not limited to diagnosed diabetics, is also on the rise, particularly across the U.S. and Europe, as consumers increasingly seek to monitor their metabolic health proactively.
Competitive Landscape
The market remains fairly consolidated, with Abbott, F. Hoffmann-La Roche Ltd., and Dexcom, Inc. accounting for the majority of the market share in 2024, according to Fortune Business Insight. These established players continue to expand their product portfolios and distribution networks, while newer entrants are carving out niches in the non-invasive monitoring space. Other notable companies shaping the competitive landscape include Medtronic, B. Braun SE, Ascensia Diabetes Care Holdings AG, Terumo Corporation, LifeScan IP Holdings, LLC, and Senseonics.
Conclusion
The blood glucose monitoring market stands at an inflection point, balancing strong structural growth drivers, namely, rising diabetes prevalence and technological innovation, against real-world challenges around affordability, diagnosis rates, and regulatory consistency. As continuous glucose monitoring systems gain further traction and non-invasive alternatives mature, the industry is poised to make diabetes management more accessible and effective for millions of patients worldwide over the coming decade.
What's Driving Japan's Market? Discover the Latest "Blood Glucose Monitoring" Insights